Published in J Virol on May 01, 1991
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol (1997) 5.73
A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J Virol (1992) 3.39
Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol (1992) 2.86
Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35
HIV-1 DNA Flap formation promotes uncoating of the pre-integration complex at the nuclear pore. EMBO J (2007) 2.17
Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J Virol (2002) 1.91
Wild-type levels of nuclear localization and human immunodeficiency virus type 1 replication in the absence of the central DNA flap. J Virol (2002) 1.62
Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J Virol (2003) 1.61
Minimal sequence requirements of a functional human immunodeficiency virus type 1 primer binding site. J Virol (1994) 1.56
Sequence and structural determinants required for priming of plus-strand DNA synthesis by the human immunodeficiency virus type 1 polypurine tract. J Virol (1996) 1.53
Nucleotide sequence and protein analysis of a complex piscine retrovirus, walleye dermal sarcoma virus. J Virol (1995) 1.47
Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J Virol (1998) 1.46
Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5' and 3' of the catalytic site. Nucleic Acids Res (1998) 1.43
Human immunodeficiency virus type 1 preintegration complexes containing discontinuous plus strands are competent to integrate in vitro. J Virol (1995) 1.43
Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J Virol (2000) 1.40
Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol (2008) 1.36
HIV infection of non-dividing cells: a divisive problem. Retrovirology (2006) 1.33
Feline lentivirus evolution in cross-species infection reveals extensive G-to-A mutation and selection on key residues in the viral polymerase. J Virol (2006) 1.20
Evaluation of the functional involvement of human immunodeficiency virus type 1 integrase in nuclear import of viral cDNA during acute infection. J Virol (2004) 1.18
Interplay between HIV entry and transportin-SR2 dependency. Retrovirology (2011) 1.17
Efficient retroviral infection of mammalian cells is blocked by inhibition of poly(ADP-ribose) polymerase activity. J Virol (1996) 1.15
Identification of a central DNA flap in feline immunodeficiency virus. J Virol (2001) 1.10
Biochemical and electron microscope analyses of the DNA reverse transcripts present in the virus-like particles of the yeast transposon Ty1. Identification of a second origin of Ty1DNA plus strand synthesis. Nucleic Acids Res (1993) 1.08
Strand displacement synthesis capability of Moloney murine leukemia virus reverse transcriptase. J Virol (1994) 1.06
Identification and characterization of an exogenous retrovirus from atlantic salmon swim bladder sarcomas. J Virol (2006) 1.05
Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise. J Biol Chem (2012) 1.03
Human spumaretrovirus-related sequences in the DNA of leukocytes from patients with Graves disease. Proc Natl Acad Sci U S A (1992) 1.02
Compensatory role of human immunodeficiency virus central polypurine tract sequence in kinetically disrupted reverse transcription. J Virol (2008) 1.00
Sequence and transcriptional analyses of the fish retroviruses walleye epidermal hyperplasia virus types 1 and 2: evidence for a gene duplication. J Virol (1999) 1.00
Posttranscriptional modification of retroviral primers is required for late stages of DNA replication. Proc Natl Acad Sci U S A (1997) 0.99
Virus strategies for passing the nuclear envelope barrier. Nucleus (2012) 0.98
Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo. J Virol (2007) 0.98
The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F. J Virol (2010) 0.96
Wild-type and central DNA flap defective HIV-1 lentiviral vector genomes: intracellular visualization at ultrastructural resolution levels. Retrovirology (2006) 0.94
Discontinuous plus-strand DNA synthesis in human immunodeficiency virus type 1-infected cells and in a partially reconstituted cell-free system. J Virol (1997) 0.92
Efficient initiation and strand transfer of polypurine tract-primed plus-strand DNA prevent strand transfer of internally initiated plus-strand DNA. J Virol (1996) 0.87
Retrotransposon suicide: formation of Ty1 circles and autointegration via a central DNA flap. J Virol (2006) 0.86
A new role for HIV nucleocapsid protein in modulating the specificity of plus strand priming. Virology (2008) 0.83
The HIV-1 passage from cytoplasm to nucleus: the process involving a complex exchange between the components of HIV-1 and cellular machinery to access nucleus and successful integration. Int J Biochem Mol Biol (2012) 0.83
Synonymous site conservation in the HIV-1 genome. BMC Evol Biol (2013) 0.82
Residual HIV-1 DNA Flap-independent nuclear import of cPPT/CTS double mutant viruses does not support spreading infection. Retrovirology (2011) 0.82
The importance of becoming double-stranded: Innate immunity and the kinetic model of HIV-1 central plus strand synthesis. Virology (2013) 0.81
SiRNA-induced mutation in HIV-1 polypurine tract region and its influence on viral fitness. PLoS One (2015) 0.75
Evaluation and prediction of the HIV-1 central polypurine tract influence on foamy viral vectors to transduce dividing and growth-arrested cells. ScientificWorldJournal (2014) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol (1975) 503.08
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol (1967) 106.91
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Nucleotide sequence of the AIDS virus, LAV. Cell (1985) 16.81
Mapping unintegrated avian sarcoma virus DNA: termini of linear DNA bear 300 nucleotides present once or twice in two species of circular DNA. Cell (1978) 13.33
Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (1987) 11.79
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol (1989) 9.37
A detailed model of reverse transcription and tests of crucial aspects. Cell (1979) 8.93
Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature (1987) 7.96
Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus. Cell (1985) 7.86
Structure, variation and synthesis of retrovirus long terminal repeat. Cell (1981) 4.90
Site on the RNA of an avian sarcoma virus at which primer is bound. J Virol (1975) 4.60
Virus-specific DNA in the cytoplasm of avian sarcoma virus-infected cells is a precursor to covalently closed circular viral DNA in the nucleus. J Virol (1978) 4.55
Involvement of reverse transcription in the replication of cauliflower mosaic virus: a detailed model and test of some aspects. Cell (1983) 4.37
Cellular functions are required for the synthesis and integration of avian sarcoma virus-specific DNA. Cell (1977) 4.06
Kinetics of synthesis, structure and purification of avian sarcoma virus-specific DNA made in the cytoplasm of acutely infected cells. J Mol Biol (1978) 4.04
Ordered interstrand and intrastrand DNA transfer during reverse transcription. Science (1988) 3.80
Studies on reverse transcriptase of RNA tumor viruses III. Properties of purified Moloney murine leukemia virus DNA polymerase and associated RNase H. J Virol (1975) 3.31
Inhibition of viral DNA synthesis in stationary chicken embryo fibroblasts infected with avian retroviruses. J Virol (1977) 2.71
Synthesis of a 600-nucleotide-long plus-strand DNA by virions of Moloney murine leukemia virus. Proc Natl Acad Sci U S A (1979) 2.39
Involvement of retrovirus reverse transcriptase-associated RNase H in the initiation of strong-stop (+) DNA synthesis and the generation of the long terminal repeat. J Virol (1984) 2.18
Synthesis of murine leukemia virus plus strong stop DNA initiates at a unique site. J Biol Chem (1982) 2.03
Studies on the single-stranded discontinuities of the cauliflower mosaic virus genome. Nucleic Acids Res (1978) 2.00
Characterization of human immunodeficiency virus type 2 envelope glycoproteins: dimerization of the glycoprotein precursor during processing. J Virol (1989) 1.93
Initiation of plus-strand DNA synthesis during reverse transcription of an avian retrovirus genome. J Virol (1984) 1.87
Viral DNA synthesized in vitro by avian retrovirus particles permeabilized with melittin. II. Evidence for a strand displacement mechanism in plus-strand synthesis. J Virol (1981) 1.87
Ribonuclease H: a ubiquitous activity in virions of ribonucleic acid tumor viruses. J Virol (1972) 1.84
Initiation of DNA synthesis by the avian oncornavirus RNA-directed DNA polymerase: structural and functional localization of the major species of primer RNA on the oncornavirus genome. Virology (1976) 1.75
RNA-primed initiation of Moloney murine leukemia virus plus strands by reverse transcriptase in vitro. J Virol (1984) 1.70
Synthesis of plus strands of retroviral DNA in cells infected with avian sarcoma virus and mouse mammary tumor virus. J Virol (1981) 1.67
Visna virus DNA: discovery of a novel gapped structure. Virology (1981) 1.51
The role of Moloney murine leukemia virus RNase H activity in the formation of plus-strand primers. J Virol (1987) 1.40
Action of the S1 endonuclease from Aspergillus oryzae on simian virus 40 supercoiled component I DNA. Biochem Biophys Res Commun (1973) 1.34
Evidence for involvement of an RNA primer in initiation of strong-stop plus DNA synthesis during reverse transcription in vitro. J Virol (1984) 1.33
Synthesis in cell culture of the gapped linear duplex DNA of the slow virus visna. Virology (1985) 1.27
Single-stranded regions on unintegrated avian retrovirus DNA. J Virol (1982) 1.27
Effect of viral RNase H on the avian sarcoma viral genome during early transcription in vitro. J Virol (1979) 1.16
Reverse transcription of avian myeloblastosis virus 35S RNA. Early synthesis of plus strand DNA of discrete size in reconstructed reactions. Nucleic Acids Res (1982) 0.99
Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (1987) 11.79
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1. J Mol Biol (1990) 4.38
HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol (1994) 4.15
Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet (1999) 3.43
A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J Virol (1992) 3.39
Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol (1996) 2.95
Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol (1998) 2.92
Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature (1987) 2.86
Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol (1998) 2.82
Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol (1995) 2.45
Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med (1987) 2.32
Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol (2000) 2.27
Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology (1985) 2.23
Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons. J Virol (1992) 2.15
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med (2001) 2.13
Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol (2001) 2.08
Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol (2001) 1.79
Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis (2001) 1.62
Relative validity and reproducibility of a French dietary history questionnaire. Int J Epidemiol (1997) 1.54
Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS (1999) 1.52
Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet (1987) 1.49
Deficient LAV1 neutralising capacity of sera from patients with AIDS or related syndromes. Lancet (1985) 1.48
Kinetic analysis of HIV-1 early replicative steps in a coculture system. AIDS Res Hum Retroviruses (1994) 1.46
Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology (1994) 1.46
A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G-->A hypermutation during negative-strand viral DNA synthesis. Virology (1995) 1.38
Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. J Virol (1997) 1.38
Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation. Virology (1996) 1.26
A monoclonal antibody against LAV gag precursor: use for viral protein analysis and antigenic expression in infected cells. J Immunol (1986) 1.25
Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J Virol (1999) 1.13
Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. AIDS (1997) 1.10
Helping people to stop smoking: randomised comparison of groups being treated with acupuncture and nicotine gum with control group. Br Med J (Clin Res Ed) (1985) 1.07
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis (2001) 1.03
The replicative impairment of Vif- mutants of human immunodeficiency virus type 1 correlates with an overall defect in viral DNA synthesis. J Gen Virol (1998) 1.02
Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother (1999) 1.02
Reversion of a polymerase-defective integrated HIV-1 genome. AIDS Res Hum Retroviruses (1993) 0.96
Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol (1999) 0.95
Variations in the risk of breast cancer associated with a family history of breast cancer according to age at onset and reproductive factors. J Clin Epidemiol (1993) 0.92
Exposure to vinyl chloride monomer: report on a cohort study. Br J Ind Med (1987) 0.89
Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses (2001) 0.88
Cholangitis in the acquired immunodeficiency syndrome: report of two cases and review of the literature. Gut (1987) 0.87
Occupational exposure and cancer of the pancreas: a review. Br J Ind Med (1991) 0.87
Breast cancer and oral contraceptives: a review. Contraception (1985) 0.87
Familial risk of breast cancer and abortion. Cancer Detect Prev (1994) 0.84
Occupational risk factors for cancer of the pancreas: a case-control study. Br J Ind Med (1990) 0.84
Lung in acquired immune deficiency syndrome: infectious and immunological status assessed by bronchoalveolar lavage. Bull Eur Physiopathol Respir (1986) 0.82
[Tobacco withdrawal. Comparison of the efficacy of various methods. Intermediate results of a comparative study]. Presse Med (1984) 0.81
Familial susceptibility to breast cancer: a complex inheritance. Int J Cancer (1989) 0.80
Dietary intake of acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Ann Oncol (2013) 0.80
Alcohol, beer and cancer of the pancreas. Int J Cancer (1990) 0.80
More on coffee and pancreatic cancer. N Engl J Med (1987) 0.79
Inhibition of HIV type 1 reverse transcriptase assay by nucleases produced by contaminating mycoplasmas. AIDS Res Hum Retroviruses (1994) 0.78
Familial risk of breast cancer in a French case-control study. Cancer Detect Prev (1994) 0.78
Plasma concentrations of fatty acids in nine European countries: cross-sectional study within the European Prospective Investigation into Cancer and Nutrition (EPIC). IARC Sci Publ (2002) 0.78
Lymphadenopathy associated virus and its etiological role in AIDS. Princess Takamatsu Symp (1984) 0.77
Alveolar macrophage phagocytosis in sarcoidosis. The role of activated lymphocytes. Ann N Y Acad Sci (1986) 0.76
Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients. HIV Clin Trials (2002) 0.75
[Viral etiology of AIDS]. Rev Prat (1986) 0.75
Summary statement on disease activity assessment. Ann N Y Acad Sci (1986) 0.75
[Techniques and methods in public health applied in oncology]. Bull Cancer (2001) 0.75
[Relation between mortality in cancer of the pancreas and food and tobacco consumption in France]. Biomed Pharmacother (1982) 0.75
[Analysis of silicone testicular implants after explantation]. J Urol (Paris) (1982) 0.75
[Evaluation of a self-assessment questionnaire with optical reader in a cohort study]. Rev Epidemiol Sante Publique (1995) 0.75
[Analysis of risk factors in arteriosclerosis obliterans of the lower extremities. Preliminary results]. Union Med Can (1981) 0.75
[LAV type II: a second retrovirus associated with AIDS in West Africa]. C R Acad Sci III (1986) 0.75
Compliance with the urine marker PABAcheck in cancer epidemiology studies. IARC Sci Publ (2002) 0.75
Association between breast cancer and family malignancies. Eur J Cancer (1991) 0.75
[Epidemiologic surveys]. Rev Prat (1989) 0.75
[Breast cancer and use of antihypertensive drugs and oral contraceptives: results of a case-control study (author's transl)]. Bull Cancer (1981) 0.75
[Epidemiological surveys]. Rev Prat (1983) 0.75